Semin Neurol 2021; 41(04): 340-347
DOI: 10.1055/s-0041-1726329
Review Article

Prevalence, Mechanisms, and Management of Ischemic Stroke in Heart Failure Patients

Hyeyoung Seol
1   Department of Neurology, McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, Texas
,
Jong S. Kim
2   Department of Neurology, University of Ulsan, Asan Medical Center, Seoul, Korea
› Institutsangaben

Abstract

Heart failure (HF) and stroke, two of the major causes of death worldwide, are closely associated. Although atrial fibrillation (AF), which occurs in more than half of patients with HF, is a major risk factor for stroke, there is a great deal of evidence that HF itself increases the risk of stroke independent of AF. The main mechanism of stroke appears to be thromboembolism. However, previous studies have failed to demonstrate the benefit of warfarin in patients with HF without AF, as the benefit of stroke prevention was counteracted by the increased incidence of major bleeding. Recently, researchers have identified patients with HF at a particularly high risk for stroke who may benefit from anticoagulation therapy. Based on stroke-risk prediction models, it may be possible to make better stroke prevention decisions for patients with HF. Moreover, non-vitamin K oral anticoagulants have emerged as anticoagulants with a more favorable risk–benefit profile than warfarin. Future studies on selecting high-risk patients and using more appropriate antithrombotics will lead to improved management of patients with HF.



Publikationsverlauf

Artikel online veröffentlicht:
13. April 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Ponikowski P, Voors AA, Anker SD. et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37 (27) 2129-2200
  • 2 Lloyd-Jones D, Adams RJ, Brown TM. et al; Writing Group Members, American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121 (07) e46-e215
  • 3 Disease GBD, Injury I, Prevalence C. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388 (10053): 1545-1602
  • 4 Ponikowski P, Anker SD, AlHabib KF. et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014; 1 (01) 4-25
  • 5 Mozaffarian D, Benjamin EJ, Go AS. et al; Writing Group Members, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016; 133 (04) e38-e360
  • 6 Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol 2016; 13 (06) 368-378
  • 7 Pullicino PM, McClure LA, Wadley VG. et al. Blood pressure and stroke in heart failure in the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Stroke 2009; 40 (12) 3706-3710
  • 8 Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983; 250 (21) 2942-2946
  • 9 Witt BJ, Brown Jr RD, Jacobsen SJ. et al. Ischemic stroke after heart failure: a community-based study. Am Heart J 2006; 152 (01) 102-109
  • 10 Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. Stroke 2011; 42 (10) 2977-2982
  • 11 Ois A, Gomis M, Cuadrado-Godia E. et al. Heart failure in acute ischemic stroke. J Neurol 2008; 255 (03) 385-389
  • 12 Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail 2009; 15 (01) 11-16
  • 13 Alberts VP, Bos MJ, Koudstaal P. et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010; 25 (11) 807-812
  • 14 Freudenberger RS, Hellkamp AS, Halperin JL. et al; SCD-HeFT Investigators. Risk of thromboembolism in heart failure: an analysis from the sudden cardiac death in heart failure trial (SCD-HeFT). Circulation 2007; 115 (20) 2637-2641
  • 15 Szummer KE, Solomon SD, Velazquez EJ. et al; VALIANT Registry. Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. Eur Heart J 2005; 26 (20) 2114-2119
  • 16 Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation 2009; 119 (18) 2516-2525
  • 17 Hohendanner F, Heinzel FR, Blaschke F. et al. Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure. Heart Fail Rev 2018; 23 (01) 27-36
  • 18 Santhanakrishnan R, Wang N, Larson MG. et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 2016; 133 (05) 484-492
  • 19 Kang SH, Kim J, Park JJ. et al. Risk of stroke in congestive heart failure with and without atrial fibrillation. Int J Cardiol 2017; 248: 182-187
  • 20 Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes. Int J Cardiol 2016; 203: 660-666
  • 21 Lip GY, Piotrponikowski P, Andreotti F. et al; Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Thromb Haemost 2012; 108 (06) 1009-1022
  • 22 Adelborg K, Szépligeti S, Sundbøll J. et al. Risk of stroke in patients with heart failure: a population-based 30-year cohort study. Stroke 2017; 48 (05) 1161-1168
  • 23 Abdul-Rahim AH, Perez AC, Fulton RL. et al; Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA), GISSI-Heart Failure (GISSI-HF) Committees and Investigators. Risk of stroke in chronic heart failure patients without atrial fibrillation: analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio Della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) trials. Circulation 2015; 131 (17) 1486-1494 , discussion 1494
  • 24 Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 1999; 33 (05) 1424-1426
  • 25 Gurbel PA, Tantry US. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail 2014; 2 (01) 1-14
  • 26 Kim JH, Shah P, Tantry US, Gurbel PA. Coagulation abnormalities in heart failure: pathophysiology and therapeutic implications. Curr Heart Fail Rep 2016; 13 (06) 319-328
  • 27 Cicala S, de Simone G, Roman MJ. et al. Prevalence and prognostic significance of wall-motion abnormalities in adults without clinically recognized cardiovascular disease: the Strong Heart Study. Circulation 2007; 116 (02) 143-150
  • 28 Choi JY, Cha J, Jung JM. et al. Left ventricular wall motion abnormalities are associated with stroke recurrence. Neurology 2017; 88 (06) 586-594
  • 29 Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25 (07) 1634-1640
  • 30 Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993; 14 (02) 205-212
  • 31 O'Connor CM, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999; 83 (09) 1345-1349
  • 32 Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103 (13) 1746-1751
  • 33 Jug B, Vene N, Salobir BG, Sebestjen M, Sabovic M, Keber I. Procoagulant state in heart failure with preserved left ventricular ejection fraction. Int Heart J 2009; 50 (05) 591-600
  • 34 Parish RC, Evans JD. Inflammation in chronic heart failure. Ann Pharmacother 2008; 42 (07) 1002-1016
  • 35 Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84 (04) 1589-1596
  • 36 Sbarouni E, Bradshaw A, Andreotti F, Tuddenham E, Oakley CM, Cleland JG. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127 (03) 607-612
  • 37 Chong AY, Freestone B, Patel J. et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006; 97 (05) 671-675
  • 38 Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol 1998; 55 (11) 1475-1482
  • 39 Dardiotis E, Giamouzis G, Mastrogiannis D. et al. Cognitive impairment in heart failure. Cardiol Res Pract 2012; 2012: 595821
  • 40 He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161 (07) 996-1002
  • 41 Kirchhof P, Benussi S, Kotecha D. et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
  • 42 January CT, Wann LS, Alpert JS. et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21) e1-e76
  • 43 Fauchier L, Lecoq C, Clementy N. et al. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project. Chest 2016; 149 (04) 960-968
  • 44 Massie BM, Collins JF, Ammon SE. et al; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119 (12) 1616-1624
  • 45 Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8 (04) 428-432
  • 46 Homma S, Thompson JL, Pullicino PM. et al; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366 (20) 1859-1869
  • 47 Cleland JG, Findlay I, Jafri S. et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148 (01) 157-164
  • 48 Zannad F, Anker SD, Byra WM. et al; COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018; 379 (14) 1332-1342
  • 49 Homma S, Thompson JL, Sanford AR. et al; WARCEF Investigators. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail 2013; 6 (05) 988-997
  • 50 Sulaica EM, Macaulay TE, Helbing RR, Abo-Aly M, Abdel-Latif A, Wanat MA. A comparison of anticoagulation, antiplatelet, and placebo treatment for patients with heart failure reduced ejection fraction in sinus rhythm: a systematic review and meta-analysis. Heart Fail Rev 2020; 25 (02) 207-216
  • 51 Madelaire C, Gislason G, Kristensen SL. et al. Low-dose aspirin in heart failure not complicated by atrial fibrillation: a nationwide propensity-matched study. JACC Heart Fail 2018; 6 (02) 156-167
  • 52 Mehra MR, Vaduganathan M, Fu M. et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. Eur Heart J 2019; 40 (44) 3593-3602
  • 53 Yancy CW, Jessup M, Bozkurt B. et al; Writing Committee Members, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128 (16) e240-e327
  • 54 Meschia JF, Bushnell C, Boden-Albala B. et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (12) 3754-3832
  • 55 Kernan WN, Ovbiagele B, Black HR. et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 (07) 2160-2236
  • 56 Kondo T, Yamada T, Morita T. et al. The CHADS2 score predicts ischemic stroke in chronic heart failure patients without atrial fibrillation: comparison to other stroke risk scores. Heart Vessels 2017; 32 (02) 193-200
  • 57 Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015; 314 (10) 1030-1038
  • 58 Ye S, Qian M, Zhao B. et al; WARCEF Investigators. CHA2 DS2-VASc score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. Eur J Heart Fail 2016; 18 (10) 1261-1266
  • 59 Lip GY, Rasmussen LH, Skjøth F, Overvad K, Larsen TB. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH) cohort study. BMJ Open 2012; 2 (04) 2
  • 60 Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. Eur J Heart Fail 2015; 17 (11) 1192-1200
  • 61 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
  • 62 Korjian S, Braunwald E, Daaboul Y. et al. Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 trial). Am J Cardiol 2018; 122 (11) 1896-1901
  • 63 Branch KR, Probstfield JL, Eikelboom JW. et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation 2019; 140 (07) 529-537